Introducing DuplexABI

CorVascular to Showcase DuplexABI™ Solution at SVU 2026 Annual Conference & Marketplace

MINNEAPOLIS, Minn., July 29, 2026. CorVascular today announced it will showcase its new DuplexABI™ solution at the Society for Vascular Ultrasound 2026 Annual Conference & Marketplace in National Harbor, Maryland. DuplexABI pairs the physiologic testing clinicians already run on VasoGuard with duplex ultrasound imaging in a single portable platform.

For a decade, the physiologic vascular lab and the imaging vascular lab have been two rooms, two instruments, and often two appointments. DuplexABI is CorVascular's move to close that gap: one cart, one operator, one workflow that runs from screening through anatomic and hemodynamic characterization.

"DuplexABI reflects exactly how CorVascular thinks about product development: practical innovation built around real clinical workflow. When vascular specialists are asked to perform an ABI assessment and a lower extremity duplex exam for the same patient, they need a solution that is efficient, portable, and easy to use. DuplexABI is designed to support both exams in one streamlined point-of-care workflow."

Doppler ankle-brachial index and photoplethysmographic toe-brachial index are the right first test. They are fast, non-invasive, inexpensive, and they answer the question of whether lower-extremity perfusion is functionally reduced.

The 2016 AHA/ACC Lower Extremity PAD Guideline sets the interpretation categories:

Every one of those results tells the clinician that something is wrong. None of them says where the lesion is, how tight it is, or whether it explains the patient's symptoms. That is the handoff point, and today it usually means scheduling the patient back for a separate duplex study.

That combination is what turns a suspicious index into an actionable finding: clarifying disease severity and extent, guiding medical therapy, identifying the patients who genuinely need advanced imaging or a revascularization referral, and establishing a baseline for follow-up.

1. 1

   Physiologic Assessment

   Doppler ABI and PPG TBI. Functional evaluation of lower-extremity perfusion.

2. 2

   Abnormal or Inconclusive Findings

   Results that trigger further evaluation.

3. 3

   Suspected Arterial Disease

   Reduced perfusion suggests possible stenosis or occlusive disease. Localization and severity still need to be defined.

4. 4

   Duplex Ultrasound

   Anatomic and hemodynamic insight. Defines the lesion and its significance.

5. 5

   Clinical Confidence

   Actionable information for diagnosis, treatment planning, and follow-up.

DuplexABI is built on the VasoGuard platform, so the physiologic half is the system clinicians already know. Segmental pressures, PVR waveforms, wearable PPG sensors, and CuffMatch™ cuff-air-volume verification all carry over unchanged.

The imaging half is integrated into the same cart and the same operator position, with a dedicated linear array probe holder, secured cable management, and a quick-release computer mount for service. The cart itself is slimmer and lighter than the existing VasoGuard cart so it moves cleanly through crowded hospital corridors and small exam rooms.

Two cart configurations are offered, sharing the same clinical capability and differing in footprint and screen size so a facility can match the system to the room it actually has.

CorVascular developed DuplexABI in collaboration with Terason, combining CorVascular's vascular diagnostic workflow expertise with Terason's established ultrasound capabilities. The result is a solution tailored for vascular specialists who want a more versatile approach to peripheral vascular assessment at the point of care.

"CorVascular understands the needs of the vascular market and how to translate those needs into meaningful workflow solutions. We are pleased to collaborate on DuplexABI and to help bring this new solution to clinicians looking for more efficient ways to integrate vascular testing and ultrasound in practice."

At SVU 2026, CorVascular will provide live demonstrations of DuplexABI, giving attendees the opportunity to see how the solution supports a more connected diagnostic workflow and complements the company's broader vascular technology strategy.

Visit CorVascular at Booth 205

July 30 to August 1, 2026 at the Gaylord National Resort in National Harbor, Maryland. Stop by the marketplace floor for live, hands-on DuplexABI and VasoGuard demonstrations.

See Event Details

DuplexABI reinforces CorVascular's commitment to delivering solutions that are clinically practical, commercially relevant, and built for the realities of modern vascular care.

CorVascular develops, manufactures, and markets innovative vascular testing technologies and is committed to its core strength in delivering accurate and reliable solutions to healthcare providers. Proudly headquartered and producing its products in the USA in the great state of Minnesota, CorVascular is privately held, eco-conscious, and an equal opportunity employer.

Teratech Corporation dba Terason, is a global medical ultrasound imaging company headquartered in Burlington, Mass. Terason was the first to patent color portable ultrasound and is a market leader in ultrasound imaging. Terason produces portable ultrasound products and technologies and has provided ultrasound systems to clinicians, hospitals, outpatient centers, and OEM partners since 2000. For more information, visit www.terason.com.

ABI and TBI interpretation categories per the 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease. Confirm thresholds against device labeling and institutional protocol. DuplexABI™ and CuffMatch™ are trademarks of CorVascular Diagnostics, LLC. VasoGuard® and CorVascular® are registered trademarks of CorVascular Diagnostics, LLC. Terason is a trademark of Teratech Corporation.